A new oral drug is showing promise in studies for treating multiple sclerosis, potentially replacing riskier injectables. After six months, Fingolimod significantly reduced brain lesions in most of the 255 patients suffering from relapsing MS, and the majority experienced a 50% drop in relapses.

Full Story:
ABC News

Related Summaries